NVS Novartis AG
- Official Name: Novartis Inc.
- Headquarters: One Health Plaza, EAST HANOVER, NJ 07936, US
- CEO: Vasant Narasimhan
- Website: novartis.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 1.881 | (1.081) - (2.962) | ||
| 2025-07-21 | 2 | Won by 1.539 | 1.322 - (0.217) | ||
| 2025-07-23 | 1R | Won by 0.032 | 1.492 - 1.460 | ||
| 2025-07-28 | 3 | Won by 0.233 | 4.409 - 4.176 | ||
| 2025-07-29 | 2R | Won by 2.153 | 1.056 - (1.097) | ||
| 2025-08-04 | 4 | Lost by 1.085 | 1.620 - 2.705 | ||
| 2025-08-06 | 2R | Lost by 2.229 | (2.702) - (0.473) | ||
| 2025-08-11 | 5 | Won by 4.176 | 1.403 - (2.773) | ||
| 2025-08-12 | 3R | Lost by 1.791 | 1.255 - 3.046 | ||
| 2025-08-18 | 6 | Lost by 0.482 | 3.972 - 4.454 | ||
| 2025-08-25 | 7 | Won by 7.894 | 4.073 - (3.821) | ||
| 2025-09-01 | 8 | Won by 1.619 | 1.358 - (0.261) | ||
| 2025-09-08 | 9 | Won by 2.939 | 1.855 - (1.084) | ||
| 2025-09-15 | 10 | Lost by 1.066 | (4.596) - (3.530) | ||
| 2025-09-22 | 11 | Lost by 2.642 | 0.042 - 2.684 | ||
| 2025-09-29 | 12 | Won by 1.109 | 0.614 - (0.495) | ||
| 2025-10-06 | 13 | Won by 7.285 TOTW | 5.293 - (1.992) | ||
| 2025-10-13 | 14 | Won by 1.018 | (2.119) - (3.137) | ||
| 2025-10-20 | 15 | Won by 0.200 | 1.947 - 1.747 |
Latest News
Yahoo - 2026-09-28
Starlink Launch Puts Globalstar Stock And Satellite Internet Shares In Focus
Space-based communications just had a spotlight moment as SpaceX’s Starship carried a fresh batch of Starlink satellites into orbit, and that test h...
Yahoo - 2026-09-27
Gecina (ENXTPA:GFC), What Is Drawing Fresh Attention Now?
Gecina (ENXTPA:GFC) has drawn investor attention after recent trading left the stock flat on the day but down over the past month and the past 3 month...
ChartMill - 2026-09-26
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile
Best Dividend Stocks screen: Novartis (NVS) offers a 3.72% yield with top profitability, but its 71% payout and weak liquidity warrant caution.
Yahoo - 2026-09-25
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell t...
Yahoo - 2026-09-25
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
Yahoo - 2026-09-25
A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team
On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called for a shake-up...
Yahoo - 2026-09-24
Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline
Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset. The dea...
Yahoo - 2026-09-24
Roche targets Novartis on IgAN market after Phase III win
Novartis gained approval of a drug in IgAN with the same target as Roche’s sefaxersen in 2026.
Yahoo - 2026-09-24
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(...
Yahoo - 2026-09-24
MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests
While remigromig is non-inferior to Lucentis in terms of efficacy, questions around its tolerability remain.
Yahoo - 2026-09-24
European Markets Close Lower in Thursday Trading as Bond Yields, Oil Prices Rise
The European stock markets closed lower in Thursday trading as bond yields and oil prices surged whi
Yahoo - 2026-09-24
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
Yahoo - 2026-09-24
Mercialys Appoints Jérôme Engelbrecht as Group CFO
PARIS, September 24, 2026--Regulatory News: Mercialys (Paris:MERY) announces the appointment of Jérôme Engelbrecht as Group CFO and member of the Ex...
Yahoo - 2026-09-24
Pharmaceutical Drug Delivery Market Forecasts Growth from $2.15T (2026) to $2.92T by 2031, Profiling J&J, Pfizer, Roche, BD & Novartis
The global pharmaceutical drug delivery market is projected to grow from USD 2.15 trillion in 2026 to USD 2.92 trillion by 2031, registering a 6.3% CA...
Yahoo - 2026-09-23
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Sefaxersen reduced proteinuria at 37 weeks, while kidney function and failure outcomes require longer observation.
Yahoo - 2026-09-23
Creatio commits $300m to scale financial AI
The new funding plan is intended to support further AI product development, alongside deployment support for use by financial institutions.
Yahoo - 2026-09-23
Roche, Ionis RNA drug scores in kidney disease study
The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from...
Yahoo - 2026-09-23
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Yahoo - 2026-09-23
European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance
All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to intern...
Show more
Yahoo - 2026-09-23
BoomRay and Novartis sign $900m deal for radioligand therapy
Yahoo - 2026-09-22
3 Integrated Oil And Gas Stocks Tied To Iran Supply Risk
Yahoo - 2026-09-22
AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’
Yahoo - 2026-09-22
Creatio Invests $300 Million in Its Bank.AI Platform to Drive AI Adoption in Financial Services
Benzinga - 2026-09-22
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Yahoo - 2026-09-22
Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move First
Yahoo - 2026-09-22
BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
Yahoo - 2026-09-21
Morgan Stanley flags Amgen's edge after heart-drug rival stumbles
Yahoo - 2026-09-21
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
Yahoo - 2026-09-21
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations
Yahoo - 2026-09-21
Melexis: update on the share buy-back program
Yahoo - 2026-09-21
Wegovy Maker Novo Looks to New Drugs to Combat Lilly, but Investors Are Unconvinced
Yahoo - 2026-09-19
What does the EU have that the U.S. does not?
Yahoo - 2026-09-19
Edison (BIT:EDNR) Shares Dropped, So What Is Driving Attention Now?
Yahoo - 2026-09-18
Novartis (SWX:NOVN) Takes Full Control Of A Brain Delivery Platform
Yahoo - 2026-09-18
Gossan Resources Announces Changes to Board and Management
Yahoo - 2026-09-18
4 Biotech Stocks to Watch as Potential Takeover Targets
Yahoo - 2026-09-18
Theranostics Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
Yahoo - 2026-09-18
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Benzinga - 2026-09-18
Dated September 17, CHMP Recommends EU Label Expansion For Novartis' Cosentyx In Polymyalgia Rheumatica After Inadequate Glucocorticoid Response Or Relapse During Taper
SeekingAlpha - 2026-09-18
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Yahoo - 2026-09-17
Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
Yahoo - 2026-09-17
A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too
Yahoo - 2026-09-17
Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
Benzinga - 2026-09-17
Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform
Yahoo - 2026-09-17
RAMSAY SANTE Group unveils "Connecting Care 2030"
Yahoo - 2026-09-16
TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry
Yahoo - 2026-09-16
Critics Warn of AI-Driven Disaster. Anthropic and Novo Are Betting on the Opposite.
Yahoo - 2026-09-16
Trialynx Wins Forge’s DPHARM Idol Disrupt 2026
Yahoo - 2026-09-16
Novartis to pay $125M for blood-brain barrier crossing platform
Yahoo - 2026-09-16
Changes in the Suominen Leadership Team
Yahoo - 2026-09-16
AstraZeneca shares oversold after trial flops and merger talk, says UBS
Benzinga - 2026-09-16
'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg
Yahoo - 2026-09-16
Sironax Announces Option Exercise and Asset Purchase
Yahoo - 2026-09-16
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Yahoo - 2026-09-15
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Yahoo - 2026-09-15
FDA clears first generic radioligand drug; Sionna turns to layoffs
Yahoo - 2026-09-15
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Yahoo - 2026-09-15
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Yahoo - 2026-09-15
Legend Naming Novartis Executive as CEO
Yahoo - 2026-09-14
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Yahoo - 2026-09-14
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
Yahoo - 2026-09-14
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
Yahoo - 2026-09-14
Palantir's AIPCon Highlights Data Sovereignty Demand, Ecosystem Adoption, Oppenheimer Says
Yahoo - 2026-09-14
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Yahoo - 2026-09-13
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
Yahoo - 2026-09-13
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone
Yahoo - 2026-09-12
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
Yahoo - 2026-09-11
Novartis: More Pain on the Way?
Yahoo - 2026-09-11
Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN)
Yahoo - 2026-09-11
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Yahoo - 2026-09-11
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
Yahoo - 2026-09-11
Amgen Drops 10% on a Trial It Didn't Even Run
Yahoo - 2026-09-11
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
Yahoo - 2026-09-11
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
Yahoo - 2026-09-11
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
Yahoo - 2026-09-11
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
Yahoo - 2026-09-10
BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)
Yahoo - 2026-09-10
High Co (STU:HIH) (H1 2026) Earnings Call Highlights: Strong Organic Growth and Strategic ...
Yahoo - 2026-09-10
Could Remibrutinib Become the Next $9 Billion Drug for Novartis?
Yahoo - 2026-09-10
Novartis stock in hot water after another key failure
Yahoo - 2026-09-10
Sector Update: Healthcare Stocks Softer Late Afternoon
Yahoo - 2026-09-10
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
Yahoo - 2026-09-10
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
Yahoo - 2026-09-10
NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week — Investor Reportedly Seeks Board Overhaul
Yahoo - 2026-09-10
Sector Update: Healthcare Stocks Softer in Afternoon Trading
Yahoo - 2026-09-10
Tecan to participate in upcoming Investor Conference
SeekingAlpha - 2026-09-10
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
Yahoo - 2026-09-10
Update: Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures
Yahoo - 2026-09-10
Artisan Partners calls for Novartis board changes amid trial, acquisition failures
Benzinga - 2026-09-10
HSBC Upgrades Novartis to Hold, Raises Price Target to $136
Yahoo - 2026-09-10
CapMan acquires Hotel Crowne Plaza Copenhagen in Denmark
Yahoo - 2026-09-10
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
Benzinga - 2026-09-10
Nvidia, FAA Join Palantir’s AI Expansion as Cyber Push Takes Off
Yahoo - 2026-09-09
Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?
Yahoo - 2026-09-09
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Yahoo - 2026-09-09
HighCo: Half-Year 2026 Results
Yahoo - 2026-09-09
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
Yahoo - 2026-09-09
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Yahoo - 2026-09-09
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls
Yahoo - 2026-09-09
Company News for Sep 9, 2026
Yahoo - 2026-09-09
Giovanni Caforio Appointed Operating Advisor to CD&R Funds
SeekingAlpha - 2026-09-09
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Yahoo - 2026-09-08
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons
Yahoo - 2026-09-08
Stock Market Today: Dow Dives, Oil Spikes After Saudi Attacks; Amgen Swoons On These Results (Live Coverage)
Yahoo - 2026-09-08
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Yahoo - 2026-09-08
Novartis Stock Tanks Following Third Major Pipeline Setback
Yahoo - 2026-09-08
AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market
Yahoo - 2026-09-08
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
Yahoo - 2026-09-08
Sector Update: Healthcare Stocks Fall Late Afternoon
Yahoo - 2026-09-08
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
Yahoo - 2026-09-08
Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says
Yahoo - 2026-09-08
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Yahoo - 2026-09-08
Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails
Yahoo - 2026-09-08
Novartis Trial Failure Sparks Biopharma Options Frenzy
Yahoo - 2026-09-08
European Stocks Close Mixed in Tuesday Trading; Oil Prices Surge As Middle East Fighting Worsens
Yahoo - 2026-09-08
Novartis’s Pipeline Just Lost Two Big Bets
SeekingAlpha - 2026-09-08
Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)
Benzinga - 2026-09-08
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Benzinga - 2026-09-08
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Benzinga - 2026-09-08
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
Benzinga - 2026-09-08
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
Benzinga - 2026-09-08
What's Going On With Amgen Stock Tuesday?
Benzinga - 2026-09-08
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
Benzinga - 2026-09-08
Why Is Eli Lilly Stock Falling Tuesday?
SeekingAlpha - 2026-09-08
NewAmsterdam Pharma: Potential Coupled With Uncertainty
SeekingAlpha - 2026-09-08
Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed
Yahoo - 2026-09-08
Novartis India acquires Pfizer brands for $132m
Benzinga - 2026-09-08
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
Benzinga - 2026-09-08
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga - 2026-09-08
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Benzinga - 2026-09-08
Market-Moving News for September 8th
Yahoo - 2026-09-08
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Benzinga - 2026-09-08
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Benzinga - 2026-09-07
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday
Yahoo - 2026-09-07
Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar
Yahoo - 2026-09-07
Novartis (NVS) Has a Potential $3 Billion MS Opportunity — But Investors Face Key Risks
Yahoo - 2026-09-07
Novartis Falls 1.9% as Pelacarsen Failure Erases CHF4.9 Billion
Yahoo - 2026-09-07
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Yahoo - 2026-09-07
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
Yahoo - 2026-09-07
Novartis Just Lost a Potential $6 Billion Drug Opportunity
Benzinga - 2026-09-07
Brent Jumps to $97, German AfD Party Wins Big: Stock Market Today
Yahoo - 2026-09-07
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
Yahoo - 2026-09-07
Novartis Shares Fall After Pelacarsen Misses Primary Goal in Late-Stage Heart Trial
Yahoo - 2026-09-07
Weight loss is just the beginning of GLP-1's: Novo Nordisk CEO
Benzinga - 2026-09-07
Reported Earlier, Royalty Pharma Prices $2B Senior Unsecured Notes Offering With $600M Due 2031 At 4.450%, $900M Due 2035 At 5.200%, And $500M Due 2055 At 5.950%
Yahoo - 2026-09-05
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Yahoo - 2026-09-04
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Yahoo - 2026-09-04
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Yahoo - 2026-09-04
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
Yahoo - 2026-09-04
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Yahoo - 2026-09-04
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Benzinga - 2026-09-04
Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events
SeekingAlpha - 2026-09-04
Ionis: Downgrading To Sell After A Series Of Unfortunate Events
Benzinga - 2026-09-04
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
Yahoo - 2026-09-04
ORLEN and partners launch Baltic Energy Initiative
Yahoo - 2026-09-04
Is Novartis (SWX:NOVN) Overvalued After Its Phase III Remibrutinib Win?
Yahoo - 2026-09-03
dorma+kaba Holding AG (DRMKY) (FY 2026) Earnings Call Highlights: Record Margins and Strategic ...
Yahoo - 2026-09-03
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
Yahoo - 2026-09-03
Novartis signs $3.2bn drug delivery deal with Alteogen
Yahoo - 2026-09-03
KN Energies joins new Baltic regional energy initiative
Yahoo - 2026-09-03
Studsvik, GE Vernova Hitachi and Samsung C&T commit to advancing 1.2 GW nuclear power project in Sweden
Yahoo - 2026-09-02
Sector Update: Healthcare Stocks Advance Late Afternoon
Yahoo - 2026-09-02
Information Regarding the Total Voting Rights and Shares of Gecina as of August 31, 2026 (1)
Yahoo - 2026-09-02
Information Regarding the Total Voting Rights and Shares of Gecina as of July 31, 2026 (1)
Yahoo - 2026-09-02
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
Yahoo - 2026-09-02
Novartis stock rises after MS drug remibrutinib trial results
Yahoo - 2026-09-02
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials
Yahoo - 2026-09-02
Global Aplastic Anemia Industry Trends and Growth Outlook 2025-2035 Featuring Profiles of Pfizer, Novartis, and Sanofi
Yahoo - 2026-09-02
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
Yahoo - 2026-09-02
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
Yahoo - 2026-09-02
Berenberg launches space coverage, initiates 4 stocks with Buy ratings
Yahoo - 2026-09-02
Composition of Suominen’s Shareholders’ Nomination Board
SeekingAlpha - 2026-09-01
Novartis: Today's Positive Remibrutinib Data Key To Unlocking Growth Plans
ChartMill - 2026-09-01
Tuesday's session: gap up and gap down stocks
Benzinga - 2026-09-01
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win
Benzinga - 2026-09-01
Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday
SeekingAlpha - 2026-08-31
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
SeekingAlpha - 2026-08-31
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
SeekingAlpha - 2026-08-26
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
SeekingAlpha - 2026-08-25
Regeneron: Why I Still See Upside After The Rally
SeekingAlpha - 2026-08-22
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
ChartMill - 2026-08-21
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors
Benzinga - 2026-08-18
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
SeekingAlpha - 2026-08-13
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
SeekingAlpha - 2026-08-13
Roche Is Getting More Benefit Of The Doubt On Improving Execution
Benzinga - 2026-08-12
10 Health Care Stocks With Whale Alerts In Today’s Session
SeekingAlpha - 2026-08-07
Amgen: The Market Is Underestimating Its Next Growth Phase
Benzinga - 2026-08-06
MHRA Approves Remibrutinib For Adults With Chronic Spontaneous Urticaria
SeekingAlpha - 2026-08-05
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
SeekingAlpha - 2026-08-05
Amgen: First $10 Billion Quarter, More Growth Ahead
Benzinga - 2026-08-03
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
SeekingAlpha - 2026-07-31
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
ChartMill - 2026-07-29
Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts
SeekingAlpha - 2026-07-28
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
SeekingAlpha - 2026-07-24
Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins
SeekingAlpha - 2026-07-24
Legend Biotech: Why I'm Ready To Go Long Again
SeekingAlpha - 2026-07-22
Novartis: The Buy Thesis Is Back (Rating Upgrade)
Benzinga - 2026-07-21
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US
SeekingAlpha - 2026-07-21
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
SeekingAlpha - 2026-07-21
Karyopharm: 'Hold' On Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck
Benzinga - 2026-07-21
Novartis Q2 2026 Earnings Call Transcript
Benzinga - 2026-07-21
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
Benzinga - 2026-07-21
Earnings Scheduled For July 21, 2026
Benzinga - 2026-07-20
Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2
Benzinga - 2026-07-20
Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate
SeekingAlpha - 2026-07-20
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity
Benzinga - 2026-07-17
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval
SeekingAlpha - 2026-07-16
Europe's Other Story: 5 Reasons The Continent's Equities Are Worth A Closer Look
Fintel - 2026-07-15
ARGUS RESEARCH CORPORATION Upgrades Novartis AG - Depositary Receipt (NVS)
Benzinga - 2026-07-13
Novartis AG Receives Health Canada Approval For Vanrafia To Reduce Preoteinuria Production In Immunoglobulin A Nephropathy Patients
SeekingAlpha - 2026-07-13
How To Build A $50,000 Dividend Portfolio In Today's Market
SeekingAlpha - 2026-07-08
A New Look At Legend Biotech: Plenty Of Upside For Carvykti
SeekingAlpha - 2026-07-07
My (Still) 21% Yielding Portfolio Update
ChartMill - 2026-07-07
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout
SeekingAlpha - 2026-07-07
Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon
Benzinga - 2026-07-06
What's Going on with Vera Therapeutics Stock on Monday?
Benzinga - 2026-07-06
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push
Benzinga - 2026-07-06
Novartis Signs Agreement To Acquire Myricx Bio For $1.1B In Upfront Payment, $400M In Potential Milestone Payments
Benzinga - 2026-07-05
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States
SeekingAlpha - 2026-07-04
Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts
Benzinga - 2026-07-02
Reported Earlier: Novartis Receives European Commission Approval For Itvisma To Treat Children With 5q Spinal Muscular Atrophy
SeekingAlpha - 2026-06-30
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
SeekingAlpha - 2026-06-25